Evidence map›Paper›PMID 41432021›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Magnesium Structure-Function Integration Platform for Spatiotemporal Multi-Modality Therapy: Combining Hormonotherapy and Immunotherapy in Prostate Cancer.

Rui Zan, Qianping Mao, Keyi Wang, Guodong Zou, Shi Yang, Hua Qiu, Xiang Fang, Guiqing Wang, Xinyi Zhou, Jiexia Wen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rui ZanDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Qianping MaoDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Keyi WangDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Guodong ZouState Key Laboratory of Metastable Materials Science and Technology, Yanshan University, Qinhuangdao, 066004, P. R. China.
Shi YangDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Hua QiuCollege & Hospital of Stomatology, Key Laboratory of Oral Diseases Research of Anhui Province, Anhui Medical University, Hefei, 230032, P. R. China.
Xiang FangSchool of Mechanical and Automotive Engineering, Shanghai University of Engineering Science, Shanghai, 201620, P. R. China.
Guiqing WangYiwu Research Institute of Fudan University, Yiwu, 322000, P. R. China.
Xinyi ZhouYiwu Research Institute of Fudan University, Yiwu, 322000, P. R. China.
Jiexia WenState Key Laboratory of Metastable Materials Science and Technology, Yanshan University, Qinhuangdao, 066004, P. R. China.
Shuai JiangDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Ran HuangDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.
Qiuming PengState Key Laboratory of Metastable Materials Science and Technology, Yanshan University, Qinhuangdao, 066004, P. R. China.
Tao SuoDepartment of Biliary Surgery, Zhongshan Hospital & College of Biomedical Engineering & Yiwu Research Institute, Fudan University, Shanghai, 200032, P. R. China.ORCID https://orcid.org/0000-0002-4146-8123

Funding

Shanghai Science and Technology Committee Rising-Star Program 24YF2704300
6 · The paper itself

Abstract

Metal-based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited by challenges such as inefficient drug delivery, low specificity, and suboptimal therapeutic outcomes. In this study, a therapeutic platform is constructed on a magnesium (Mg) surface utilizing self-healing thiolated hyaluronic acid (HA-SH) and cell membrane-derived vesicle (CMV) drug system, which improves structural stability, enables spatiotemporal drug release, and facilitates immune-hormone combination therapy for prostate cancer. CMV with phospholipid bilayers promotes HA-SH disulfide bond interactions through weak hydrophobic interactions, mitigating corrosion and ensuring structural integrity. Additionally, HA-SH exhibits glutathione (GSH)-responsive drug release within the tumor microenvironment. CMV facilitates pH-sensitive drug delivery and enables efficient cytoplasmic entry via membrane fusion mechanisms, ensuring precise spatiotemporal control. Through drug library screening, ginsenoside Rb1 is identified as a key therapeutic agent, competitively inhibiting androgen receptor signaling. Coupled with hydrogen release from Mg, it induces immunogenic cell death and promotes the formation of tertiary lymphoid structures (TLS) via inhibiting the PI3K-AKT pathway, achieving synergistic androgen deprivation therapy and immune activation. This implantable drug delivery system effectively tackles mechanical stability, local drug delivery, and systemic immune activation concerns, demonstrating substantial translational promise for various malignancies to improve treatment effectiveness and reduce structural failure risks.

Indexed as

Hormone Replacement TherapyImmunotherapyMagnesiumProstatic NeoplasmsAnimalsCell Line, TumorCombined Modality TherapyDrug Delivery SystemsMaleMiceMice, Inbred BALB CMice, Inbred C57BLTumor MicroenvironmentMagnesiumandrogen deprivation therapyimmunogenic cell deathmulti‐modality therapyspatiotemporal responsestructure‐function integration

Identifiers

PMID41432021
PMCPMC12948271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.